FindTrial
Sign In

Functional imaging in localisation of pheochromocytoma

Performance of 68Ga-DOTATATE,131I â??MIBG and18Fâ??FDG PET in localisation of PPGLâ?? a single centre experience

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/04/018409
Enrollment
100
Registered
2019-04-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C7A8- Other malignant neuroendocrine tumors

Interventions

Intervention1: nil: nil Control Intervention1: nil: nil

Sponsors

No
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Proven PPGL 2.Conventional (CT / MRI) imaging available 3.Atleast one other functional imaging available â??68Ga-DOTATATE or 131I â??MIBG or 18Fâ??FDG PET

Exclusion criteria

Exclusion criteria: 1.Incomplete data

Design outcomes

Primary

MeasureTime frame
To find sensitivities of each functional imaging (68Ga-DOTATATE PET/CT or 131I â??MIBG or 18Fâ??FDG PET/CT) imaging in diagnosis of PPGL with respect to per-patient, per-region and per-lesion analysisTimepoint: 1 year—

Secondary

MeasureTime frame
Comparison of sensitivities of various functional imaging modalities and conventional imaging in diagnosis of PPGL with respect to per-patient, per-region and per-lesion analysisTimepoint: 1 year—

Countries

India

Contacts

Public ContactDr Tushar Bandgar

Department of Endocrinology, Seth GSMC and KEM Hospital

drtusharb@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026